Alnylam Pharmaceuticals | ALNY - Employees Total Number

Stock Price
457.15
Daily Change
5.15 1.14%
Monthly
5.09%
Yearly
80.58%
Q3 Forecast
448.25

Alnylam Pharmaceuticals reported 2.23K in Employees for its fiscal year ending in December of 2024.



Financials
Stock Price USD
Assets USD 4.57B
Cash and Equivalent USD 1.11B
Cost of Sales USD 142.95M
Current Assets USD 3.64B
Current Liabilities USD 1.3B
Debt USD 1.3B
EBIT USD 4.89M
EBITDA USD 18.83M
Employees 2.23K
EPS Earnings Per Share USD 0.32
Equity Capital and Reserves USD 250.59M
Gross Profit on Sales USD 630.74M
Interest Expense on Debt USD 40.25M
Interest Income USD 27.49M
Loan Capital USD 1.03B
Market Capitalization USD 59.08B
Net Income USD -66.28M
Operating Expenses USD 789.89M
Operating Profit USD -16.2M
Ordinary Share Capital USD 130.98M
Pre-Tax Profit USD -35.36M
Sales Revenues USD 773.69M
Selling and Administration Expenses USD 323.31M
Stock USD 71.69M
Trade Creditors USD 102.39M
Trade Debtors USD 567.11M

Employees Change Date
Acadia Pharmaceuticals 597 86 Dec/2023
Agios Pharmaceuticals 486 103 Dec/2024
Alnylam Pharmaceuticals 2.23K 130 Dec/2024
Amgen 28K 1.3K Dec/2024
Arrowhead Research 609 84 Sep/2024
BioMarin Pharmaceutical 3.04K 361 Dec/2024
Incyte 2.62K 93 Dec/2024
Ionis Pharmaceuticals 1.07K 142 Dec/2024
Moderna 5.8K 200 Dec/2024
Neurocrine Biosciences 1.8K 400 Dec/2024
Novartis 101.7K 2.62K Dec/2022
PTC Therapeutics 939 49 Dec/2024
Sanofi EUR 91.57K 3.87K Dec/2022
Sarepta Therapeutics 1.37K 58 Dec/2024
Takeda 49.28K 1.93K Mar/2024
Tectonic Therapeutic 45 1 Dec/2023
Ultragenyx Pharmaceutical 1.29K 18 Dec/2024
Vertex Pharmaceuticals 6.1K 700 Dec/2024
Xencor 250 30 Dec/2024